Protocol Ledger

NCT06448312 · Phase III · ACTIVE NOT RECRUITING

A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Interventional Phase III clinical trial protocol NCT06448312 sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-06-07 Enrollment: 406 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06448312
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)406 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06448312
Protocol FieldVerified Registry Value
NCT IdentifierNCT06448312
Consolidated Lead SponsorSichuan Kelun-Biotech Biopharmaceutical Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment406 participants (ESTIMATED)
Registered Start Date2024-06-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06448312
Hospital Research SiteLocationSite Profile
Cancer Hospital Chinese Academy of Medical SciencesBeijing, ChinaOpen Hospital Dossier ->
Jilin Cancer HospitalChangchun, ChinaOpen Hospital Dossier ->
The First Hospital of Jilin UniversityChangchun, ChinaOpen Hospital Dossier ->
Hunan Cancer HospitalChangsha, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI